Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

被引：0

作者：

Park, Jae ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 11期

关键词：

BLINATUMOMAB; THERAPY; ADULTS;

D O I：

10.6004/jnccn.2019.5030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting. However, most adult patients still die of ALL despite these therapies, with or without hematopoietic stem cell transplant. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jae Park summarized clinical data from key trials of novel immunotherapies in ALL and reviewed evidence-based treatment approaches for adults with relapsed/refractory B-cell ALL.

引用

页码：1448 / 1450

页数：3

共 6 条

[1]

Advani AS, 2018, BLOOD S1, V132

[2] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [J].

Goekbuget, Nicola ;

Dombret, Herve ;

Bonifacio, Massimiliano ;

Reichle, Albrecht ;

Graux, Carlos ;

Faul, Christoph ;

Diedrich, Helmut ;

Topp, Max S. ;

Brueggemann, Monika ;

Horst, Heinz-August ;

Havelange, Violaine ;

Stieglmaier, Julia ;

Wessels, Hendrik ;

Haddad, Vincent ;

Benjamin, Jonathan E. ;

Zugmaier, Gerhard ;

Nagorsen, Dirk ;

Bargou, Ralf C. .

BLOOD, 2018, 131 (14) :1522-1531

[3] Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia [J].

Kantarjian, Hagop ;

Stein, Anthony ;

Goekbuget, Nicola ;

Fielding, Adele K. ;

Schuh, Andre C. ;

Ribera, Josep-Maria ;

Wei, Andrew ;

Dombret, Herve ;

Foa, Robin ;

Bassan, Renato ;

Arslan, Onder ;

Sanz, Miguel A. ;

Bergeron, Julie ;

Demirkan, Fatih ;

Lech-Maranda, Ewa ;

Rambaldi, Alessandro ;

Thomas, Xavier ;

Horst, Heinz-August ;

Brueggemann, Monika ;

Klapper, Wolfram ;

Wood, Brent L. ;

Fleishman, Alex ;

Nagorsen, Dirk ;

Holland, Christopher ;

Zimmerman, Zachary ;

Topp, Max S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09) :836-847

[4] Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia [J].

Kantarjian, Hagop M. ;

DeAngelo, Daniel J. ;

Stelljes, Matthias ;

Martinelli, Giovanni ;

Liedtke, Michaela ;

Stock, Wendy ;

Gokbuget, Nicola ;

O'Brien, Susan ;

Wang, Kongming ;

Wang, Tao ;

Paccagnella, M. Luisa ;

Sleight, Barbara ;

Vandendries, Erik ;

Advani, Anjali S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :740-753

[5] Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia [J].

Maude, S. L. ;

Laetsch, T. W. ;

Buechner, J. ;

Rives, S. ;

Boyer, M. ;

Bittencourt, H. ;

Bader, P. ;

Verneris, M. R. ;

Stefanski, H. E. ;

Myers, G. D. ;

Qayed, M. ;

De Moerloose, B. ;

Hiramatsu, H. ;

Schlis, K. ;

Davis, K. L. ;

Martin, P. L. ;

Nemecek, E. R. ;

Yanik, G. A. ;

Peters, C. ;

Baruchel, A. ;

Boissel, N. ;

Mechinaud, F. ;

Balduzzi, A. ;

Krueger, J. ;

June, C. H. ;

Levine, B. L. ;

Wood, P. ;

Taran, T. ;

Leung, M. ;

Mueller, K. T. ;

Zhang, Y. ;

Sen, K. ;

Lebwohl, D. ;

Pulsipher, M. A. ;

Grupp, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :439-448

[6] Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia [J].

Park, Jae H. ;

Riviere, Isabelle ;

Gonen, Mithat ;

Wang, Xiuyan ;

Senechal, Brigitte ;

Curran, Kevin J. ;

Sauter, Craig ;

Wang, Yongzeng ;

Santomasso, Bianca ;

Mead, Elena ;

Roshal, Mikhail ;

Maslak, Peter ;

Davila, Marco ;

Brentjens, Renier J. ;

Sadelain, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :449-459

← 1 →